BlackRock
RNTX

BlackRock’s Rein Therapeutics RNTX Stock Holding History

BlackRock’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
326,204
+257,676
+376% +$312K ﹤0.01% 4678
2026
Q1 		$89.1K Buy
68,528
+13,522
+25% +$16.8K ﹤0.01% 4985
2025
Q4 		$63.8K Buy
55,006
+2,132
+4% +$2.94K ﹤0.01% 4998
2025
Q3 		$60.5K Buy
52,874
+1,438
+3% +$1.83K ﹤0.01% 4944
2025
Q2 		$72K Buy
51,436
+133
+0.3% +$239 ﹤0.01% 4913
2025
Q1 		$90.8K Sell
51,303
-27,650
-35% -$58K ﹤0.01% 4791
2024
Q4 		$182K Buy
78,953
+27,673
+54% +$83.8K ﹤0.01% 4640
2024
Q3 		$182K Buy
51,280
+19,995
+64% +$53.4K ﹤0.01% 4545
2024
Q2 		$86.7K Buy
+31,285
New +$129K ﹤0.01% 4736
2024
Q1 		– Sell
-189
Closed -$576 – 5413
2023
Q4 		$576 Hold
189
– – ﹤0.01% 5283
2023
Q3 		$287 Hold
189
– – ﹤0.01% 5373
2023
Q2 		$338 Hold
189
– – ﹤0.01% 5439
2023
Q1 		$234 Hold
189
– – ﹤0.01% 5512
2022
Q4 		$448 Sell
189
-1
-0.5% -$3 ﹤0.01% 5670
2022
Q3 		$1K Hold
190
– – ﹤0.01% 5775
2022
Q2 		$1K Sell
190
-9,520
-98% -$87.4K ﹤0.01% 5826
2022
Q1 		$100K Sell
9,710
-464
-5% -$4.2K ﹤0.01% 5286
2021
Q4 		$114K Buy
10,174
+448
+5% +$6.93K ﹤0.01% 5233
2021
Q3 		$198K Sell
9,726
-207
-2% -$4.54K ﹤0.01% 4994
2021
Q2 		$249K Buy
+9,933
New +$248K ﹤0.01% 4852
2020
Q2 		– Sell
-2,322
Closed -$15K – 5161
2020
Q1 		$15K Sell
2,322
-628
-21% -$7.56K ﹤0.01% 4662
2019
Q4 		$34K Sell
2,950
-32
-1% -$316 ﹤0.01% 4591
2019
Q3 		$40K Buy
2,982
+508
+21% +$7.03K ﹤0.01% 4567
2019
Q2 		$36K Buy
2,474
+1,589
+180% +$41.7K ﹤0.01% 4624
2019
Q1 		$35K Sell
885
-54
-6% -$1.68K ﹤0.01% 4528
2018
Q4 		$16K Buy
939
+85
+10% +$3.42K ﹤0.01% 4611
2018
Q3 		$47K Buy
854
+35
+4% +$2.35K ﹤0.01% 4550
2018
Q2 		$88K Sell
819
-10,979
-93% -$1.24M ﹤0.01% 4479
2018
Q1 		$1.92M Sell
11,798
-78
-0.7% -$13.9K ﹤0.01% 3687
2017
Q4 		$2.5M Buy
11,876
+56
+0.5% +$13.4K ﹤0.01% 3628
2017
Q3 		$3.16M Buy
+11,820
New +$2.96M ﹤0.01% 3596

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

BlackRock's RNTX Position: Q2 2026 in Review

BlackRock increased its Rein Therapeutics (RNTX) stake by 376% in Q2 2026, buying an estimated $312K and bringing the position to 326,204 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #4678.

BlackRock first reported a position in RNTX in Q3 2017 and has held it in 31 quarters since. The position peaked at $3.16M in Q3 2017. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • BlackRock held 326,204 shares of Rein Therapeutics worth $339K as of Q2 2026.
  • BlackRock bought 257,676 Rein Therapeutics shares in Q2 2026, an estimated $312K.
  • Rein Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4678 holding.
  • BlackRock first reported a position in Rein Therapeutics in Q3 2017 and has held it in 31 quarters since.
  • BlackRock's Rein Therapeutics position peaked at $3.16M in Q3 2017.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.